GTX (GTXI) Reaches New 1-Year Low at $1.30

GTx, Inc. (NASDAQ:GTXI) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $1.30 and last traded at $1.33, with a volume of 5922 shares changing hands. The stock had previously closed at $1.35.

Several research firms recently commented on GTXI. Zacks Investment Research lowered shares of GTX from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. ValuEngine lowered shares of GTX from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Stifel Nicolaus lowered shares of GTX from a “buy” rating to a “hold” rating in a report on Friday, September 21st. Robert W. Baird lowered shares of GTX from an “outperform” rating to a “neutral” rating and set a $17.00 price target on the stock. in a report on Friday, September 21st. Finally, BidaskClub lowered shares of GTX from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Five investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $21.25.

The company has a market cap of $31.51 million, a PE ratio of -0.73 and a beta of 1.60.

GTX (NASDAQ:GTXI) last posted its quarterly earnings data on Thursday, November 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). As a group, equities research analysts forecast that GTx, Inc. will post -1.65 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. raised its stake in shares of GTX by 57.6% during the second quarter. Point72 Asset Management L.P. now owns 170,250 shares of the biopharmaceutical company’s stock valued at $2,607,000 after purchasing an additional 62,250 shares during the period. Citadel Advisors LLC purchased a new stake in shares of GTX during the second quarter valued at approximately $296,000. Strs Ohio purchased a new stake in shares of GTX during the second quarter valued at approximately $163,000. Federated Investors Inc. PA raised its stake in shares of GTX by 68.1% during the second quarter. Federated Investors Inc. PA now owns 147,539 shares of the biopharmaceutical company’s stock valued at $2,259,000 after purchasing an additional 59,754 shares during the period. Finally, BlackRock Inc. raised its stake in shares of GTX by 129.5% during the second quarter. BlackRock Inc. now owns 390,150 shares of the biopharmaceutical company’s stock valued at $5,973,000 after purchasing an additional 220,114 shares during the period. Institutional investors own 12.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “GTX (GTXI) Reaches New 1-Year Low at $1.30” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/12/08/gtx-gtxi-reaches-new-1-year-low-at-1-30.html.

About GTX (NASDAQ:GTXI)

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

Further Reading: Growth Stocks

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply